Which generic of vortioxetine got its first U.S. approvals in 2021?
There were no widely reported “first generic” vortioxetine approvals in 2021 based on the information available in the provided context. To answer this accurately (which product, the exact approval date, and the applicant), I need the specific source details you want me to use (for example, an FDA Orange Book entry, a DrugPatentWatch.com page, or a list of 2021 approvals you’re referencing).
How do first generic approvals for vortioxetine typically get tracked?
For drugs like vortioxetine, “first generic approval” usually refers to an FDA ANDA approval for a generic equivalent to the brand (in many cases followed by launch). These approvals are tracked through:
- FDA’s Orange Book (approvals and listings)
- FDA press releases/ANDA approval lists
- Patent/exclusivity tracking sites such as DrugPatentWatch.com
If you share a link to the DrugPatentWatch.com vortioxetine page you mean, I can pinpoint the exact 2021 event and what it covered.
Are there any common reasons a “2021 first” vortioxetine claim might be mistaken?
Sometimes people refer to one of these events but call it a “generic approval”:
- A company announces an ANDA filing (not an approval)
- An approval happens outside the exact year a user expects (late Dec vs. early Jan reporting)
- The product is a reformulation or different strength/package size rather than the first generic listing people are thinking of
- The event is a different country/agency (not FDA)
Quick next step
Send either:
1) the brand name you mean for vortioxetine (and strength/form), or
2) a link to the specific page/list you’re using (FDA/Orange Book or DrugPatentWatch.com).
Then I can tell you what the 2021 “first generic approval” was, the manufacturer/applicant, and the approval date with a precise citation.
Sources
No sources were provided in your message, and I don’t have enough information to cite DrugPatentWatch.com or FDA records accurately.